Abstract：Objective:To observe the recental effect between the Intravenouschemotherapy(IVCT)and the transarterial chemoembolization(TACE)on cervical cancer.Methods:Sixty patients with cervical cancer in our department of obstetrics and gynecology were randomly divided into 30 patients with intravenous chemotherapy (IVCT) and 30 patients with arterial chemoembolization (TACE). Effective rate ,surgical rate ,complicaions and thevarious pathlogical risk factors incidence were analyzed and recompared .Results:Compared with IVCT group, the effective rate and surgical rate of TACE group was increased remarkably ,which was difference significantly(36.7%和53.3%,χ2=14.217,P=0.042; 73.3%和93.3%,χ2=12.905,P=0.047); Compared with IVCT group, The incidence rate of myelosuppression, gastrointestinal reaction and White blood cells reduce in TACE group were lower than those of IVCT group,which were difference significantly(χ2=16.718,36.904,18.412,P=0.038,0.0079,0.031); The incidence rate of parsmetrial involvement and deep muscleinfiltration,lymphnodemetastasis and vascularcercinomaboltransferring in TACE group were lower than those of IVCT group,which were difference significantly (χ2=17.370,21.090,31.813,P=0.036,0.024,0.0081).Conclusion: TACE is better than that of IVCT in neoadjuvant chemotherapy on cervical cancer,especially in reducing the thevarious pathlogical risk factors incidence.
李梅, 邓春霞. 不同用药方式的新辅助化疗对中晚期宫颈癌的疗效比较[J]. 河北医学, 2019, 25(4): 626-628.
LI Mei, DENG Chunxia. Comparison of the Effects of Neoadjuvant Chemotherapy with Intravenous Chemotherapy and Arterial Embolization Chemotherapy on Advanced Cervical Cancer. HeBei Med, 2019, 25(4): 626-628.
[1] Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane Database Syst Rev,2012,(12)12:746~749. [2] Matsumura M, Takeshima N, Ota T, et al. Neoadjuvant chemotherapy followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for Stage IB2-IIB cervical cancer-irinotecan and platinum chemotherapy[J]. Gynecol Oncol,2010 ,119(2):212~216. [3] Robova H, Rob L, Halaska MJ, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer[J]. Gynecol Oncol,2013,128(1):49~53. [4] Monk B,Huang HQ,Celia D,et al.Quality of life outcomes from a randomized phase H1 trial of cisplatin with or without topoteean in advanced carcinoma of the cervix:a gynecologic oneology group study[J].Clin Oncol,2005,23:4617~4625. [5] 张云艳,靳红,于丽波,等.三种新辅助化疗方案在宫颈癌治疗中的应用和比较[J].哈尔滨医科大学学报,2009,43(5):484~485,489. [6] 杨琳琳,杨宏英,杨谢兰,等.两种新辅助化疗方案辅助治疗86例局部晚期宫颈癌的疗效观察[J].重庆医学,2013,42(2):199~201. [7] 焦蓉,陈莉.介入化疗及全身静脉化疗在宫颈癌术前治疗中疗效比较[J].中国社区医师,2013,15(1):140~141.
2019, Vol. 25 
冀公网安备13080202000677号